Anti-CD20 mAb such as rituximab have proven highly effective at improving outcome in Bcell malignancies. However, many patients ultimately relapse and become refractory to treatment. The glycoengineered anti-CD20 mAb obinutuzumab was developed to induce enhanced antibody dependent cellular cytotoxicity, antibody dependent phagocytosis and direct cell death and was shown to lead to improved outcomes in a randomized study in Bchronic lymphocytic leukemia (B-CLL). We hypothesized that immune stimulation through TLR7 agonism in combination with obinutuzumab would further enhance lymphoma clearance and the generation of long-term anti-tumor immune responses. Here we demonstrate in syngeneic human CD20-expressing models of lymphoma that systemic administration of a TLR7 agonist (R848) increases responses when administered in combination with obinutuzumab and protects against disease recurrence. Depletion studies demonstrate that primary anti-tumor activity is dependent on both NK cells and CD4 + T-cells but not CD8 + T-cells. However, both CD4 + and CD8 + T-cells appear necessary for the generation of protective immunological memory. Importantly, increased tumor-free survival post obinutuzumab and R848 combination therapy was seen in human CD20 (hCD20) transgenic mice which express hCD20 on normal B-cells. These findings provide a rationale for clinical testing of obinutuzumab in combination with systemically administered TLR7
Introduction
Non-hodgkin lymphoma and chronic lymphocytic leukemia account for around 9% of all new cancers diagnosed in the US annually and continue to represent a significant therapeutic challenge.
(1) The anti-CD20 monoclonal antibody (mAb) rituximab has significantly improved survival (2, 3) but many patients ultimately relapse, necessitating the development of novel therapies and improved anti-CD20 mAbs. The glycoengineered anti-CD20 mAb obinutuzumab was developed to have enhanced antibody-dependent cellular cytotoxicity (ADCC) (4) and antibody-dependent phagocytosis (ADCP) (5) due to enhanced FcRIII binding affinity and induces profound direct programmed cell death (PCD). (6) A number of in vitro and pre-clinical xenograft studies demonstrated the superiority of obinutuzumab over rituximab (7) which was confirmed in a phase III trial in chronic lymphocytic leukemia, leading to its licensing by the FDA (8) and in combination with bendamustine for the treatment of rituximab refractory/relapsed follicular lymphoma. (9) Evidence suggests that adaptive immunity may play a role in durable responses seen after anti-CD20 mAb therapy with pre-treatment T-cell levels linked to clinical outcome postrituximab (10) and the presence of idiotype-specific T-cells post-treatment. (11) Furthermore, we have demonstrated that obinutuzumab induces the release of damage-associated molecular pattern molecules (DAMPs) which can prime dendritic cell (DC) maturation and T-cell activation. (12) Recent data has demonstrated the importance of the tumor microenvironment in regulating T-cell responses, which has led to intense interest in manipulating the balance between positive immune-stimulatory signals and negative regulatory signals with immunomodulatory agents. (13) Toll-like receptors (TLR) are expressed on immune cells which, upon engagement by DAMPs and pathogen associated molecular patterns (PAMPs) trigger a cascade of signaling pathways, leading to production of pro-inflammatory cytokines, polarization of T-cell responses and activation of antigen presenting cells (APCs). TLR7 is an endosomally located receptor whose natural ligand is viral uridine and guanosine rich single-stranded RNA. Synthetic agonists of TLR7/8 have been shown to activate plasmacytoid and myeloid DC, stimulate production of type I interferons and stimulate strong T H -1 immunity and CD8 + T-cell responses. (14, 15) The only TLR7/8 agonist licensed to date (Imiquimod) is currently administered as a topical treatment for basal cell carcinoma and other dermatological malignancies. Recently, topical administration of resiquimod (R848) was shown to induce regression of both treated and non-treated cutaneous T-cell lymphoma lesions' suggesting the induction of adaptive immunity, which was further evidenced by expansion of benign Tcell clones and effector function. (16) We have previously shown that systemic administration of TLR7 agonist (R848) in combination with radiation can prime CD8 + T-cell responses which mediate anti-tumor activity in murine lymphoma models. (17) A number of novel TLR7/8
agonists are currently in pre-clinical development and clinical testing (NCT02556463).
Therefore, we chose to use R848, which binds selectively to mouse TLR7, to develop a syngeneic murine lymphoma model to investigate whether TLR7 agonism can enhance the efficacy of anti-CD20 antibodies through priming of T-cell responses. We demonstrate that R848 can enhance the therapeutic efficacy of obinutuzumab, leading to long-term survival and anti-tumor immunity though an NK and CD4 + T-cell dependent mechanism, providing proof of principle for translation to the clinic. experiments were repeated at least once. Mice were culled when they developed palpable tumor masses or CNS disease (onset of hind leg paralysis).
Methods

Antibodies and reagents
The EL4 (TIB-39) and Raji (CCL-86) lymphoma cell lines were obtained from ATCC (LGC Standards, UK) and maintained in RPMI 1640 supplemented with 10% FCS, 2mM Lglutamine, 25mM Hepes (Sigma-Aldrich, UK) and 50nM 2-mercatoethanol. Cells were routinely screened to confirm absence of mycoplasma.
Generation of EL4 expressing human CD20
EL4hCD20 cells were generated as described in Supplementary Methods (Supplementary Figure 1) .
Tumor Therapy
Mice were inoculated intra-venously (i.v.) with 5x10 5 EL4-hCD20 via the tail vein. 50µg obinutuzumab m2a or saline was administered intra-peritoneal (i.p.) on day 1, 4, 7, 11 and 14 (C57Bl/6) or day 7, 11, 14, 18, 21 (hCD20Tg 
Detection of cytokine secreting T-cells from treated mice
Splenocytes were co-cultured with irradiated EL4hCD20 tumor cells (30Gy) at a ratio of 3.5:1 for 5 days in 100IU/ml human IL-2 (Proleukin, Prometheus) and re-stimulated for a further 17
hours with irradiated EL4hCD20 tumor cells at a 1:1 ratio in 100IU/ml IL-2 and Brefeldin-A.
Cells were stained as detailed in Supplementary Methods.
Assessment of NK cell activation in treated mice
Splenocytes were cultured for 4 hours in the presence of Brefeldin A or monensin and antiCD107a-PE (eBioscience, #12-1071) at 10 7 /ml in 96-well plates pre-coated with 10g/ml obinutuzumab m2a overnight at 4C in borate buffer where indicated. Cells were stained for IFN as detailed in Supplementary Methods.
ADCC and ADCP
ADCC and ADCP assays were performed as described in the Supplementary Methods.
Statistical Methods
All statistical analysis was undertaken using GraphPad PRISM software as detailed in Supplementary Methods. P values less than 0.05 were deemed significant. Although obinutuzumab has been shown to be superior to rituximab in Phase III clinical trials, rituximab remains the most commonly used anti-CD20 antibody in the clinic. We therefore compared obinutuzumab to rituximab in combination with R848 and found that both combinations were equally as effective with 80% LTS (Figure 2c , P=0.0005 versus saline, P=0.94 obinutuzumab plus R848 versus rituximab plus R848). Given that rituximab is non-glycoengineered this suggests that the glycoengineering of obinutuzumab was not important in this model.
Results
Systemic
Obinutuzumab and R848 combination therapy efficacy is dependent on CD4 and NK cells.
In order to improve clinical outcome for patients receiving anti-CD20 mAb the generation of long-term immunological memory is key to preventing tumor relapse. As obinutuzumab plus R848 combination treated LTS were protected from tumor rechallenge this suggests priming of adaptive immunity. We therefore investigated the role that T-cells and NK cells played during therapy. fold (Figure 7b ).
Discussion
We demonstrate that addition of systemically administered TLR7 agonist R848 to obinutuzumab therapy can significantly enhance long-term survival in syngeneic models of lymphoma. Importantly we also demonstrated improved survival in lymphoma bearing hCD20Tg mice which more closely mimics the patient population with expression of human CD20 on B-cells.
This is the first report that the anti-tumor efficacy of obinutuzumab can be significantly improved by systemic administration of a TLR7 agonist. Although R848 can enhance nonspecific NK cell cytotoxicity, ADCC and ADCP the in vivo mechanism of action appeared to be solely dependent on NK cells and CD4 + T-cells. A type I anti-CD20 mAb was previously shown to eradicate EL4hCD20 cells in C57Bl/6 mice by the same mechanism. (19, 20) Taken together with data that R848 and other TLR agonists can increase levels of activating FcR but decrease levels of the inhibitory FcRIIb (21, 22) this suggests that R848 is potentiating of CpG was not effective and as a result only local tumor control secondary to local administration was seen. (27, 28) In this model NK cells were again shown to be the major effector cell with no apparent role for T-cells or macrophages: no loss of therapy was seen in clodronate-liposome treated mice. However, when a CpG oligonucleotide 1018 ISS was combined with rituximab subcutaneously in a phase II clinical trial the response rate was similar to that reported for rituximab alone. (29) Although infiltration of CD8 + T-cells and macrophages into tumor was observed these data suggest that systemic administration of TLR agonists may be beneficial for sustained anti-tumor responses.
The relative role of the different anti-CD20 mAb effector mechanisms in eradicating malignant disease in patients remains unclear, although there is evidence that Fc-mediated mechanisms are important as patients with FcR polymorphisms which bind the rituximab Fc region with higher affinity respond better to rituximab therapy. (30) In murine models some studies report a primary role for phagocytic mechanisms. (26, 31) , (32, 33) However, others have demonstrated the importance of ADCC by NK cells and these studies used a similar EL4hCD20 model to ours, (19, 20) suggesting that the mechanism of action may vary depending agonism. (34) TLR agonists can potentially play a diverse role in activating the immune system and thus may enhance antibody-mediated tumor cell killing by numerous different mechanisms. Given that both anti-CD20 mAb (20) and R848 therapy (35, 36) can prime Th1
immune responses through NK cell-mediated IFN release and production of IL-12 by DC, and that TLR7 agonism (37, 38) leads to direct induction of CD4 T-cell proliferation and stimulation of CD4 T-cells through activation of APC, it is likely that obinutuzumab and R848 act in synergy to activate tumor-specific CD4 + T-cells. It was previously shown in wild-type mice bearing EL4hCD20 that protection from tumor rechallenge post anti-CD20 mAb therapy was restricted to hCD20 + tumors, suggesting a vaccination effect. (33) Here we show that hCD20Tg mice, which express human CD20 on B-cells and are tolerized to human CD20, are also protected from tumor rechallenge post-combination therapy. This suggests that the addition of an immunostimulatory TLR7 agonist is able to extend the repertoire of tumorspecific T-cells to non-foreign antigens.
Given that combination therapy led to protection from tumor rechallenge, it was surprising that there was no role for CD8 + T-cells in primary therapy. Although obinutuzumab can induce immunogenic cell death, (12) in this model enhanced NK cell-mediated ADCC may eradicate tumor before establishment of a tumor-specific CD8 mediated T-cell response.
However, although IFN secreting tumor-specific CD8 + T-cells were not detected posttherapy, depletion of CD8 + T-cells during the course of therapy appeared critical for generation of immunological memory as over half of these mice were not protected from rechallenge, in agreement with a previous report. (19) Given that CD4 + T-cell depletion also reduced protection from rechallenge it is likely that both T-cell subsets are acting in concert to prime long-term immunological memory. (39) The novel glycoengineered type II anti-CD20 mAb obinutuzumab has previously been shown to be highly effective in vitro (4) (5) (6) 40) and in xenograft models.
(41-43) Here, we demonstrate the ability of obinutuzumab to treat lymphoma in mice with an intact immune system. Although the majority of mice had increased survival with obinutuzumab mono-therapy, long-term survival was low. Given that the glycoengineering of obinutuzumab enhances its affinity to FcRIIIa and that mouse FcRIV, the murine homologue of human FcRIIIa, is not expressed on mouse NK cells (44) it is impossible to determine the effects of enhanced ADCC by glycoengineered obinutuzumab in this model. However, our data demonstrates that combination therapy with a TLR7 agonist can significantly enhance long-term survival.
Moreover, a similar enhanced efficacy was seen when the non glyco-engineered type I antibody rituximab was combined with R848, suggesting that TLR7 agonists can potentiate the efficacy of all anti-CD20 antibodies and not just glycoengineered type II anti-CD20
antibodies.
The impact of immune-modulatory therapies on clinical practice is currently being realized with durable remissions in a number of solid cancers post immune checkpoint blockade. (13) Whilst to date the role of immune checkpoint molecules in lymphoma is still emerging, the data presented here is encouraging and suggests that the anti-tumor activity of anti-CD20
antibodies can be enhanced by combination approaches with immune-stimulatory agents.
Strategies to improve the efficacy of anti-CD20 mAb therapy and provide enhanced antitumor immunity would appear highly likely to lead to improved patient survival. There is currently an unmet need to develop combination approaches to enhance anti-CD20
antibodies through immune modulation and systemic administration of TLR agonists, in particular those targeting TLR7, may be highly effective in combination with the novel anti-CD20 mAb obinutuzumab and appear worthy of further clinical investigation.
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